Center-Authored Papers

Filters: Author is Bowen, James D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
United States Food and Drug Administration
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
United States
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Wang L-S, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JGD, Cannon-Albright L, Baldwin CT, Zetterberg H et al..  2015.  Rarity of the Alzheimer disease-protective APP A673T variant in the United States.. JAMA neurology. 72(2):209-16. Abstract
Treatment Outcome
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R et al..  2010.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(8):1076-83. Abstract
Treatment Failure
Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA.  2008.  Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain : a journal of neurology. 131(Pt 2):e89;authorreplye90.
Transplantation, Autologous
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R et al..  2010.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(8):1076-83. Abstract
Sweden
Wang L-S, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JGD, Cannon-Albright L, Baldwin CT, Zetterberg H et al..  2015.  Rarity of the Alzheimer disease-protective APP A673T variant in the United States.. JAMA neurology. 72(2):209-16. Abstract
Stroke Volume
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Shared Resources
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Safety
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Retrospective Studies
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Research Trials Office Core Facility - Biostatistics Service
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Registries
Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R et al..  2010.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(8):1076-83. Abstract
RECURRENCE
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Receptor, EphA1
Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK et al..  2011.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.. Nature genetics. 43(5):436-41. Abstract
Public Health Sciences Division
Gray SL, Anderson ML, Hubbard RA, Lacroix A, Crane PK, McCormick W, Bowen JD, McCurry SM, Larson EB.  2013.  Frailty and Incident Dementia.. The journals of gerontology. Series A, Biological sciences and medical sciences. Abstract
McDavid A, Crane PK, Newton KM, Crosslin DR, McCormick W, Weston N, Ehrlich K, Hart E, Harrison R, Kukull WA et al..  2013.  Enhancing the power of genetic association studies through the use of silver standard cases derived from electronic medical records.. PloS one. 8(6):e63481. Abstract
Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK et al..  2011.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.. Nature genetics. 43(5):436-41. Abstract
Protective Factors
Wang L-S, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JGD, Cannon-Albright L, Baldwin CT, Zetterberg H et al..  2015.  Rarity of the Alzheimer disease-protective APP A673T variant in the United States.. JAMA neurology. 72(2):209-16. Abstract
Polymorphism, Single Nucleotide
Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK et al..  2011.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.. Nature genetics. 43(5):436-41. Abstract
Pedigree
Wang L-S, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JGD, Cannon-Albright L, Baldwin CT, Zetterberg H et al..  2015.  Rarity of the Alzheimer disease-protective APP A673T variant in the United States.. JAMA neurology. 72(2):209-16. Abstract
Patient Dropouts
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract